Antibody targeting osteoclast-related protein Siglec-15

US9114131B2 · kind B2 · utility

Assignee

• DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

• Ichiro Watanabe · Tokyo, JP
• Yoshiharu Hiruma · Tokyo, JP
• Eisuke Tsuda · Tochigi, JP
• Tatsuji Matsuoka · Tokyo, JP
• Toshiaki Ohtsuka · Tokyo, JP
• Tohru Takahashi · Tokyo, JP
• Toshinori Agatsuma · Tokyo, JP
• Sandra Miller · Munich, DE
• Robert Mühlbacher · Gräfelfing, DE
• Kathrin-Ladetzki Baehs · Gräfelfing, DE
• Steffen Runz · Heidelberg, DE
• Ulrike Schubert · Birkenfeld, DE
• Ingrid Schuster · Munich, DE
• Dirk Ponsel · Germering, DE

Key dates

• Filing date: Oct 4, 2011
• Grant date: Aug 25, 2015
• Expiry date: Nov 5, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.